#None #Boston #gastric cancer #Antennova #ATN-022

Antennova Presents Promising Data on ATN-022

At the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025 (ASCO GI 2025), Antennova, a biotech firm specialized in oncology, disclosed key results from their Phase I/II CLINCH study focusing on ATN-022, an antibody-drug conjugate targeting CLDN18.2, specifically in patients with advanced or metastatic gastric cancer.

Study Overview

The CLINCH study, currently being conducted in China and Australia, consists of two phases: a dose escalation phase followed by a dose expansion phase. As of November 22, 2024, data from 21 patients undergoing the dose expansion phase showed a Overall Response Rate (ORR) of 42.9%. Among those, 9 patients experienced partial responses (PRs), with 8 confirmed, and 11 patients showed stable disease (SD). This high rate of disease control signifies the potential effectiveness of ATN-022 even in difficult-to-treat gastric cancer patients.

Further analysis involved 10 gastric cancer patients whose CLDN 18.2 expression was below the threshold of 20%. This subgroup revealed an ORR of 30%, comprising 1 complete response (CR) and 2 PRs, all noted as confirmed cases. Impressively, one patient receiving treatment has exhibited a durable response while being part of the study for over 14 months.

Safety and Tolerance

The results highlighted ATN-022's manageable safety profile. This is a crucial aspect in late-stage cancer treatments where patients often bear various side effects from existing therapies. The promising preliminary antitumor activity observed across different levels of CLDN18.2 expression further supports the need for ongoing clinical investigations into ATN-022’s capabilities in target patients.

Future Endeavors

Antennova is actively enrolling patients for further dose optimization and is exploring treatment options for patients with other solid tumors. The ongoing efforts align with the company’s commitment to expanding therapeutic targets in oncology.

Poster Presentation Details

• - Title: Safety and Preliminary Efficacy of ATG-022 in Patients with Advanced/Metastatic Gastric Cancer (CLINCH)
• - Abstract Number: 456
• - Session: Poster Session A Cancers of Esophagus and Stomach and Other Gastrointestinal Cancers
• - Presenter: Jinfeng Ma, Shanxi Cancer Hospital
• - Date: Thursday, January 23, 2025
• - Time: 11:30 AM - 1:00 PM (Pacific time)

3:30 AM - 5:00 AM, January 24, 2025 (Beijing time)

About ATN-022

ATN-022, also referred to as ATG-022, is engineered to target the CLDN18.2 protein, critical in the adhesion mechanisms of cancer cells. It operates differently than standard therapies as it aims to confront the cellular changes caused by cancer progression. With recognition by the U.S. FDA through Orphan Drug Designations for both gastric and pancreatic cancers, ATN-022's scope as a potential novel treatment option has grown.

The ongoing data trends from Antennova's CLINCH study suggest that ATN-022 could become a competitive player in the treatment landscape for advanced gastric cancer. By encapsulating the right mechanism and targeting the molecules relevant in cancer degradation, it also hints at the possibility of enhanced treatment options for patients across varying stages and types of cancer.

Conclusion

Antennova's promising results from the ASCO GI 2025 reinforce the significance of targeting CLDN18.2 and strengthens the case for continued research and development in ensuring better therapeutic outcomes for patients suffering from advanced forms of gastric cancer. As further patient enrollments proceed, the medical community watches closely for the next wave of findings that could revolutionize treatment paradigms in oncology.